This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2003 Aug;4(8):459-60.

doi: 10.1016/s1470-2045(03)01163-x.

Breast cancer trial with erythropoietin terminated unexpectedly

Brian Leyland-Jones¹; BEST Investigators and Study Group

Affiliations

PMID: 12901958
DOI: 10.1016/s1470-2045(03)01163-x

Breast cancer trial with erythropoietin terminated unexpectedly

Brian Leyland-Jones et al. Lancet Oncol. 2003 Aug.

. 2003 Aug;4(8):459-60.

doi: 10.1016/s1470-2045(03)01163-x.

Authors

Brian Leyland-Jones¹; BEST Investigators and Study Group

Affiliation

¹ McGill University, Montreal, Canada.

PMID: 12901958
DOI: 10.1016/s1470-2045(03)01163-x

No abstract available

PubMed Disclaimer

Comment in

Amgen's point of view on epoetins.
Seidenberg B, Perlmutter RM. Seidenberg B, et al. Lancet Oncol. 2004 Apr;5(4):206-7. doi: 10.1016/S1470-2045(04)01422-6. Lancet Oncol. 2004. PMID: 15050950 No abstract available.

Similar articles

Controversial effect of epoetin in cancer: grounds for a translational research exercise?
Apolone G. Apolone G. Eur J Cancer. 2004 Jun;40(9):1289-91. doi: 10.1016/j.ejca.2003.12.024. Eur J Cancer. 2004. PMID: 15177486 No abstract available.
Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z, DeSantis ER. Crouch Z, et al. Am J Health Syst Pharm. 2009 Jul 1;66(13):1180-5. doi: 10.2146/ajhp080214. Am J Health Syst Pharm. 2009. PMID: 19535656 Review.
FDA panel scrutinizes safety of anti-anemia drugs.
Randal J. Randal J. J Natl Cancer Inst. 2004 Jul 21;96(14):1061. doi: 10.1093/jnci/96.14.1061. J Natl Cancer Inst. 2004. PMID: 15265966 No abstract available.
Erythropoietin: high profile, high scrutiny.
Crawford J. Crawford J. J Clin Oncol. 2007 Mar 20;25(9):1021-3. doi: 10.1200/JCO.2006.08.8153. Epub 2007 Feb 20. J Clin Oncol. 2007. PMID: 17312331 No abstract available.
Erythropoietin pathophysiology and erythropoietin deficiency anemia.
Cazzola M. Cazzola M. Hematol J. 2004;5 Suppl 3:S100-3. doi: 10.1038/sj.thj.6200432. Hematol J. 2004. PMID: 15190288 Review. No abstract available.

See all similar articles

Cited by

Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy.
Platek ME, Reid ME, Wilding GE, Jaggernauth W, Rigual NR, Hicks WL Jr, Popat SR, Warren GW, Sullivan M, Thorstad WL, Khan MK, Loree TR, Singh AK. Platek ME, et al. Head Neck. 2011 Nov;33(11):1561-8. doi: 10.1002/hed.21640. Epub 2010 Dec 15. Head Neck. 2011. PMID: 21990220 Free PMC article.
Erythropoietin or darbepoetin for patients with cancer.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Tonia T, et al. Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5. Cochrane Database Syst Rev. 2012. PMID: 23235597 Free PMC article.
Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro.
Abhold E, Rahimy E, Wang-Rodriguez J, Blair KJ, Yu MA, Brumund KT, Weisman RA, Ongkeko WM. Abhold E, et al. BMC Res Notes. 2011 Dec 21;4:553. doi: 10.1186/1756-0500-4-553. BMC Res Notes. 2011. PMID: 22188703 Free PMC article.
Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy.
Kitano T, Tada H, Nishimura T, Teramukai S, Kanai M, Nishimura T, Misawa A, Yoshikawa K, Yasuda H, Ishiguro H, Matsumoto S, Yanagihara K, Fukushima M. Kitano T, et al. Int J Hematol. 2007 Jul;86(1):37-41. doi: 10.1532/IJH97.07040. Int J Hematol. 2007. PMID: 17675265
Recombinant human erythropoietin and overall survival.
Loprinzi CL. Loprinzi CL. Curr Oncol Rep. 2005 Jul;7(4):269-70. doi: 10.1007/s11912-005-0049-2. Curr Oncol Rep. 2005. PMID: 15946585 No abstract available.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information